Pursuant to the Plan, on the Effective Date, Paul Keglevic, Paul Aronzon, Alex Clavel, Elizabeth LaPuma, Henry S. Miller, David Tolley and Vikas Parekh ceased to be directors of the Company and were replaced by Anant Yardi, Jason Yardi, Adnan Ahmad, Arnold Brier, Daniel Ehrmann and Jagannath Iyer.
Appointed
Jagannath Iyer
Director
WeWork Inc.
Effective
2024-06-11
Filed
June 12, 2024, 7:59 PM ET
Pursuant to the Plan, on the Effective Date, Paul Keglevic, Paul Aronzon, Alex Clavel, Elizabeth LaPuma, Henry S. Miller, David Tolley and Vikas Parekh ceased to be directors of the Company and were replaced by Anant Yardi, Jason Yardi, Adnan Ahmad, Arnold Brier, Daniel Ehrmann and Jagannath Iyer.
On June 7, 2024, the board of directors (the “Board”) of Vera Therapeutics, Inc. (the “Company”) appointed Christy Oliger to the Board, effective immediately.
On June 6, 2024, Brett P. Seabert, serving as a Director and Audit Committee Chair on the Board of Directors (the “Board”) of Rocky Mountain Chocolate Factory, Inc. (the “Company”), notified the Board of his intention to resign effective June 6, 2024.
On June 7, 2024, Michael Hartmeier submitted his resignation as a member of the Board of Directors (the "Board") of Full House Resorts, Inc. (the "Company"), effective immediately.
Upon the closing of the Offering and the resulting reduction in the outstanding shares of Class C common stock and Class D common stock, on June [12], 2024, Sean Sullivan, who served as the remaining Class C Director, resigned from the Board in accordance with the Certificate of Incorporation and the Stockholders Agreement.
On June 10, 2024, Anat Ashkenazi, a director of Maravai LifeSciences Holdings, Inc. (the “Company”), informed the Board of Directors of the Company (the “Board”) that she plans to resign from the Board effective as of July 31, 2024, in consideration of the time commitments associated with her pending appointment as Chief Financial Officer of Alphabet Inc.
On June 9, 2024, Mr. Scipio “Max” Carnecchia tendered his resignation as a member of the Board of Directors of Mitek Systems, Inc. (the “Company”) effective immediately.
On June 10, 2024, the Board of Directors (the “ Board ”) of Bread Financial Holdings, Inc. (the “ Company ”) voted to increase the size of the Board to ten directors and appointed Praniti Lakhwara as a director and member of the Risk & Technology Committee, all effective as of June 10, 2024.
On June 9, 2024, Barbara Nelson, a member of the Board of Directors of the Company (the “Board”), the Chair of the Nominating and Governance Committee of the Board and a member of the Audit Committee of the Board, notified the Company of her decision not to stand for reelection when her current term expires at the Company’s 2024 Annual Meeting of Stockholders.
On June 7, 2024, the Board of Directors (the “Board”) of BRC Inc. (the “Company”) increased the size of the Board from six to eight members and appointed Mr. Lawrence “Chip” Molloy and Major General Retired Clayton Hutmacher to fill the vacancies created by such increase in the size of the Board.
On June 7, 2024, the Board of Directors (the “Board”) of BRC Inc. (the “Company”) increased the size of the Board from six to eight members and appointed Mr. Lawrence “Chip” Molloy and Major General Retired Clayton Hutmacher to fill the vacancies created by such increase in the size of the Board.
On June 6, 2024, Mr. Charles “Chuck” L. Prow resigned from his position as a Class I Director of the Company’s Board of Directors, effective June 16, 2024.
Appointed
Toichi Takino
Director
Deciphera Pharmaceuticals, Inc.
Effective
2024-06-11
Filed
June 11, 2024, 7:59 PM ET
Toichi Takino and Masayuki Tanigawa became members of Deciphera’s board of directors
Departed
Dennis L. Walsh
Director
Deciphera Pharmaceuticals, Inc.
Effective
2024-06-11
Successor
Toichi Takino and Masayuki Tanigawa
Filed
June 11, 2024, 7:59 PM ET
Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera
Departed
James A. Bristol
Director
Deciphera Pharmaceuticals, Inc.
Effective
2024-06-11
Successor
Toichi Takino and Masayuki Tanigawa
Filed
June 11, 2024, 7:59 PM ET
Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera
Departed
Ron Squarer
Director
Deciphera Pharmaceuticals, Inc.
Effective
2024-06-11
Successor
Toichi Takino and Masayuki Tanigawa
Filed
June 11, 2024, 7:59 PM ET
Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera
Departed
Frank S. Friedman
Director
Deciphera Pharmaceuticals, Inc.
Effective
2024-06-11
Successor
Toichi Takino and Masayuki Tanigawa
Filed
June 11, 2024, 7:59 PM ET
Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera
Departed
Patricia L. Allen
Director
Deciphera Pharmaceuticals, Inc.
Effective
2024-06-11
Successor
Toichi Takino and Masayuki Tanigawa
Filed
June 11, 2024, 7:59 PM ET
Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera
Departed
Susan L. Kelley
Director
Deciphera Pharmaceuticals, Inc.
Effective
2024-06-11
Successor
Toichi Takino and Masayuki Tanigawa
Filed
June 11, 2024, 7:59 PM ET
Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera
Departed
Edward J. Benz, Jr.
Director
Deciphera Pharmaceuticals, Inc.
Effective
2024-06-11
Successor
Toichi Takino and Masayuki Tanigawa
Filed
June 11, 2024, 7:59 PM ET
Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera
Appointed
Masayuki Tanigawa
Director
Deciphera Pharmaceuticals, Inc.
Effective
2024-06-11
Filed
June 11, 2024, 7:59 PM ET
Toichi Takino and Masayuki Tanigawa became members of Deciphera’s board of directors
Departed
John R. Martin
Director
Deciphera Pharmaceuticals, Inc.
Effective
2024-06-11
Successor
Toichi Takino and Masayuki Tanigawa
Filed
June 11, 2024, 7:59 PM ET
Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera
On June 7, 2024, Jonathan Coslet notified Cushman & Wakefield plc (the “Company”) of his decision to resign from the Board, effective immediately, which the Board accepted.
Mario Dell’Aera Jr., David Golden, Michael Huseby, Steven Panagos, Vice Admiral John Ryan, Rory Wallace, and Raphael Wallander resigned from the Company’s Board of Directors.
Mario Dell’Aera Jr., David Golden, Michael Huseby, Steven Panagos, Vice Admiral John Ryan, Rory Wallace, and Raphael Wallander resigned from the Company’s Board of Directors.
Mario Dell’Aera Jr., David Golden, Michael Huseby, Steven Panagos, Vice Admiral John Ryan, Rory Wallace, and Raphael Wallander resigned from the Company’s Board of Directors.
Mario Dell’Aera Jr., David Golden, Michael Huseby, Steven Panagos, Vice Admiral John Ryan, Rory Wallace, and Raphael Wallander resigned from the Company’s Board of Directors.
Mario Dell’Aera Jr., David Golden, Michael Huseby, Steven Panagos, Vice Admiral John Ryan, Rory Wallace, and Raphael Wallander resigned from the Company’s Board of Directors.
Mario Dell’Aera Jr., David Golden, Michael Huseby, Steven Panagos, Vice Admiral John Ryan, Rory Wallace, and Raphael Wallander resigned from the Company’s Board of Directors.
Mario Dell’Aera Jr., David Golden, Michael Huseby, Steven Panagos, Vice Admiral John Ryan, Rory Wallace, and Raphael Wallander resigned from the Company’s Board of Directors.
Hwan-Yoon F. Chung advised EnerSys’ board of directors (the “Board”) of his decision not to stand for re-election to the Board for the upcoming annual meeting of the stockholders in 2024 (the “2024 Annual Meeting”) in order to focus on his other commitments.
Departed
Rabia Gurses Ozden, M.D.
Director
Adverum Biotechnologies, Inc.
Effective
2024-06-10
Successor
Szilárd Kiss, M.D.
Filed
June 11, 2024, 7:59 PM ET
Dr. Ozden notified the Board of her decision to resign from the Board and the Research and Development Committee of the Board, effective June 10, 2024.
Appointed
Szilárd Kiss, M.D.
Director
Adverum Biotechnologies, Inc.
Effective
2024-06-10
Filed
June 11, 2024, 7:59 PM ET
appointed Szilárd Kiss, M.D. as a director to fill the vacancy on the Board created by Dr. Ozden’s resignation.
Adam Koppel notified Solid Biosciences Inc. (the “Company”) of his decision to resign as a member of the Company’s Board of Directors (the “Board”), effective as of June 11, 2024.
On June 4, 2024, the Board of Directors (the “Board”) of Euronet Worldwide, Inc. (the “Company”) increased the size of the board from nine to ten directors, and appointed Mr. Sergi N. Herrero to the Board.
On June 6, 2024, Dr. Whitney Haring-Smith, notified the Company of his decision to resign from the board of directors of the Company (the “Board”) effective immediately.
On June 9, 2024, Li Han, a member of the Board of Directors (the “Board”) of Faraday Future Intelligent Electric Inc., a Delaware corporation (the “Company”), notified the Board that she will resign as a director of the Company for personal reasons, effective immediately.
On June 10, 2024, Murray Roos resigned from the Board of Directors (the " Board ") of Tradeweb Markets Inc. (the " Company "), effective as of such date.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.